Navigation Links
Champions Announces Technology Collaboration Utilizing Champions' Tumorgraft™ Technology Platform for Oncology Drug Development
Date:3/24/2011

BALTIMORE, March 24, 2011 /PRNewswire/ -- Champions Biotechnology, Inc. (OTC: CSBR) ("Champions") announced today the signing of a technology collaboration agreement with Cephalon, Inc. in which Champions will conduct low passage Tumorgraft™ studies on two proprietary chemical compounds, CEP-32496, an inhibitor of mutant B-Raf, and CEP-37440, a selective dual ALK-FAK inhibitor, provided by Cephalon to determine the activity or response in potential clinical indications.  The results of these studies will be used to inform the future clinical development path of these compounds.  

Cephalon will pay Champions an initiation fee of $1,390,000 by April 15, 2011, and will, under certain conditions, also pay Champions various amounts upon achieving certain milestones.  Potential milestone payments under the Agreement total $27 million.  In addition, under certain conditions, Cephalon will pay Champions royalties on any commercialized products developed under the Agreement.

Guy Malchi, Champion's head of corporate development commented, "This is our largest Translational Oncology Services contract to date and provides us with a great foundation for strong revenue growth for our next fiscal year.  We are very excited to be partnering with an innovative company like Cephalon that can utilize our technology to improve the process of oncology drug development.  The potential for future milestone and royalty payments in these contracts will allow us to capture a portion of the financial upside our technology generates for our customers.  We hope this is just the beginning of a productive and long term partnership between our companies."

Jeffry Vaught, Cephalon's Executive Vice President for R&D said, "Our collaboration with Champions Biotechnology significantly compliments our oncology discovery capabilities by providing wider access to more clinically relevant and predictive pre-clinical oncology models. In ad
'/>"/>

SOURCE Champions Biotechnology, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Champions Biotechnology Reports Fiscal 2009 Third Quarter Financial Results
2. Champions Biotechnology, Inc. Establishes UK Subsidiary and Retains General Manager to Expand Its Personalized Oncology Business
3. Champions Biotechnology Partners with Do-Coop Technologies to Advance Its Novel Oncology Compound Into Biomerk Tumorgraft(TM) Testing
4. Champions Biotechnology Reports Fiscal 2009 Full-Year Financial Results
5. Champions Biotechnology to Deploy its Technology to Guide Development of Oncology Therapeutic for Global Biotech Leader
6. Champions Biotechnology to Present at Rodman & Renshaws Eleventh Annual Healthcare Conference
7. Champions Biotechnology and PinnacleCare Enter Into Personalized Oncology Collaboration Agreement
8. Champions Biotechnology Reports Fiscal 2010 First Quarter Financial Results
9. Champions Biotechnology Expands Collaboration to Test Oncology Therapeutic in Biomerk Tumorgrafts(TM)
10. Champions Biotechnology to Present Data at AACR-EORTC 2009 Regarding the Predictability of Biomerk Tumorgraft(TM) Platform to Guide Personalized Cancer Treatment and Accelerate Oncology Drug Development
11. Champions Biotechnology Enters into Licensing Agreement with Yale University and Southern Research Institute for the Repurposing of Bithionol for Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/19/2014)... , Aug. 19, 2014 CSSi, the leader ... recently announced the formation of the company,s Medical and ... the addition of Dr. William E. Gannon, Jr. ... http://photos.prnewswire.com/prnh/20140818/136957 The MCAB, with Dr. ... of therapeutic areas and set strategic goals for the ...
(Date:8/19/2014)... 19, 2014 /PRNewswire/ - iCo Therapeutics Inc. ("iCo" or ... results of its Oral Amphotericin B (Oral Amp ... study, conducted by ImmuneCarta®, the immune monitoring business ... effectiveness of Oral Amp B in reactivating latent ... despite intensive treatment with antiretroviral therapy. ...
(Date:8/18/2014)... Tampa, FL (Aug. 18, 2014) -- A new ... South Florida (USF) Morsani College of Medicine and ... the life-threatening complications of interventional cardiovascular disease treatment. ... model that the novel molecular therapy could selectively ... healing following a medical procedure using a balloon ...
(Date:8/18/2014)... Aug. 18, 2014   Sterne, Kessler, Goldstein & ... Washington, DC , announced today that ... Review (IPR) with the U.S. Patent and Trademark ... of BioReference Laboratories, Inc. (Nasdaq: BRLI).  These IPR petitions ... by Myriad Genetics, Inc. These patents have been asserted ...
Breaking Biology Technology:CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 2CSSi Appoints Dr. William E. Gannon, Jr. to Newly Formed Medical and Clinical Advisory Board 3iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 2iCo Therapeutics Announces Positive Oral Amphotericin B Study Results 3Selective therapy may improve artery repair after interventional cardiovascular procedures 2Selective therapy may improve artery repair after interventional cardiovascular procedures 3Sterne Kessler Files 11 IPR Petitions On Behalf Of GeneDx, Inc., Subsidiary Of BioReference Laboratories, Inc. 2Sterne Kessler Files 11 IPR Petitions On Behalf Of GeneDx, Inc., Subsidiary Of BioReference Laboratories, Inc. 3
... NOVATO, Calif., March 31 BioMarin,Pharmaceutical Inc. (Nasdaq ... (AnGes), BioMarin,s marketing and distribution partner in Japan, ... from the Japanese Ministry of Health, Labour and ... VI ( MPS,VI)., "We are proud to ...
... performance module implemented in just few months, organization kicks ... ... personal growth, OTTAWA, March ... employee performance and talent management software,today announced that Beaumont Hospitals ...
... March 31 Transave Inc.,reported today that its ... have the ability to penetrate mucus and,biofilms, and ... patients with cystic fibrosis, according to results of ... Results of the study titled "Biofilm penetration, ...
Cached Biology Technology:Naglazyme Approved by Japanese Ministry of Health 2Naglazyme Approved by Japanese Ministry of Health 3Naglazyme Approved by Japanese Ministry of Health 4Beaumont Hospitals in Michigan Selects Halogen Software for Pay for Performance System 2Study Confirms Anti-Infective ARIKACE(TM) Effectively Penetrates Mucus and Biofilm, and Kills Pseudomonas, a Bacteria Plaguing Cystic Fibrosis Patients 2Study Confirms Anti-Infective ARIKACE(TM) Effectively Penetrates Mucus and Biofilm, and Kills Pseudomonas, a Bacteria Plaguing Cystic Fibrosis Patients 3Study Confirms Anti-Infective ARIKACE(TM) Effectively Penetrates Mucus and Biofilm, and Kills Pseudomonas, a Bacteria Plaguing Cystic Fibrosis Patients 4
(Date:8/20/2014)... of 158 pregnant teenagers in Rochester, NY, nearly half ... of ice, cornstarch, vacuum dust, baby powder and soap, ... , Moreover, such teens had significantly lower iron levels ... substances. , Pregnant teens, regardless of pica, are at ... iron deficiency and anemia. Low iron in pregnant teens ...
(Date:8/20/2014)... , Aug. 20, 2014 /CNW/ -  Issue ... and can quickly become life threatening for some children.    ... as 1.2 million Canadians have food allergies and this number ... cent of children are estimated to have food allergies.  ... mild skin irritations and hives to breathing difficulties and loss ...
(Date:8/20/2014)... WORCESTER, MA Using population-based screening outcomes of approximately ... states, including four researchers at the University of Massachusetts ... combined immunodeficiency (SCID) can be successfully implemented across public ... programs published in the Aug. 20 issue of the ... JAMA ) showed the rate of SCID in newborns ...
Breaking Biology News(10 mins):Pica in pregnant teens linked to low iron 2Information Update - Allergens and food safety at school - What's in your child's lunch? 2Information Update - Allergens and food safety at school - What's in your child's lunch? 3Newborn screening expansion offers early diagnosis and treatment to infants with SCID 2Newborn screening expansion offers early diagnosis and treatment to infants with SCID 3
... 2007 Today, researchers report for the first ... that are inherited only from the motherare directly linked ... study, which highlights the role of mitochondrial genome variation ... in Genome Research ( www.genome.org ). ...
... (NPL) is part of Biotesting Europe, a new 358,000 ... will ensure that future testing procedures and facilities meet ... in this growing industry. Biometric recognition systems measure ... can be as varied as iris images, fingerprints, the ...
... smoking can be harmful, if not deadly. While the desire ... factors also play an important role. The etiology of these ... the environment. Adoption and twin studies have shown that the ... studies have provided evidence that ones sex can influence the ...
Cached Biology News:Scientists show that mitochondrial DNA variants are linked to risk factors for type 2 diabetes 2UK scientists working to help cut ID theft 2Does the desire to consume alcohol and tobacco come from our genetic makeup? 2Does the desire to consume alcohol and tobacco come from our genetic makeup? 3
LECHNER AND LaVECK MEDIUMfor the clonal growth of normal human bronchial and other epithelial cells. Requires additives. With glutamine.Recommended storage condition:oC to 8oCIntended use(s):research...
...
... Modules Highly efficient ... cloning into advanced λ ... For flexibility ... Systems, the modules of ...
... While antigen and antibody-based immunoaffinity ... been reused many times without compromising ... extremes and chaotropic agents has precluded ... Western blotting. The CHEMICON Re-Blot ...
Biology Products: